Panacea Biotec Ltd. has announced a significant contract worth approximately $4.75 million with the Pan American Health Organization (PAHO) for the supply of its Easyfive-TT vaccine. The deal is part of a Long-Term Agreement that mandates the delivery of the Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae type B (DTP-HepB-Hib) vaccine over the calendar years 2026 and 2027. This agreement underscores Panacea Biotec's commitment to addressing global health needs, particularly in providing essential vaccines to organizations like PAHO, a regional office of the World Health Organization.

The contract entails the supply of Easyfive-TT, a liquid pentavalent vaccine, which is designed for single-dose administration. The contract will be executed based on the orders received from PAHO, ensuring that the vaccine meets the organization’s requirements as stipulated. With this award, Panacea Biotec stands to bolster its revenue and enhance its international presence in the pharmaceutical sector, particularly in the vaccine market. The total value of the contract amounts to about ₹41 Crore, indicative of the company's robust operational capabilities and market demand for its products.

This award from PAHO not only reinforces Panacea Biotec's position in the international market but also highlights its role in global vaccination efforts. As the company moves forward with this agreement, it emphasizes the absence of any related party transactions, ensuring transparency and compliance with SEBI regulations. This contract marks a crucial step for Panacea Biotec as it continues to expand its footprint in the biopharmaceutical industry, catering to vital public health needs worldwide.